Pharma: Clinic Roundup

• Bristol-Myers Squibb Co., of New York, and Pfizer Inc., also of New York, said results from a prespecified subanalysis of the ARISTOTLE trial were published in Circulation, showing that the reductions in stroke or systemic embolism, number of major bleeding events and mortality demonstrated with Eliqus (apixaban) compared to warfarin were consistent across subgroups defined based on levels of International Normalized Ratio control in patients with nonvalvular atrial fibrillation.